Randomized Phase II Study of Docetaxel plus Bevacizumab or Pemetrexed plus Bevacizumab for Elderly Non-Squamous NSCLC (TORG1323)

被引：0

作者：

Kozuki, Toshiyuki ^{[1
]}

Nogami, Naoyuki ^{[1
]}

Yamashita, Natsumi ^{[2
]}

Shinkai, Tetsu ^{[3
]}

Shukuya, Takehito ^{[4
,5
]}

Seki, Nobuhiko ^{[6
]}

Kato, Terufumi ^{[7
]}

Satouchi, Miyako ^{[8
]}

Masuda, Noriyuki ^{[9
]}

Watanabe, Koshiro ^{[10
]}

机构：

[1] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan

[2] Natl Hosp Org, Shikoku Canc Ctr, Clin Res Ctr, Matsuyama, Ehime, Japan

[3] Shonan East Gen Hosp, Dept Internal Med, Chigasaki, Kanagawa, Japan

[4] Juntendo Univ, Fac Med, Div Resp Med, Tokyo, Japan

[5] Grad Sch Med, Tokyo, Japan

[6] Teikyo Univ, Sch Med, Dept Med Oncol, Tokyo 173, Japan

[7] Kanagawa Cardiovasc & Resp Ctr, Resp Med, Yokohama, Kanagawa, Japan

[8] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan

[9] Kitasato Univ, Sch Med, Dept Resp Med, Kanagawa, Japan

[10] Thorac Oncol Res Grp, Yokohama, Kanagawa, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

elderly; Clinical Trial in Progress; NSCLC; bevacizumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.01-085

引用

页码：S666 / S666

页数：1

共 50 条

[31] 65 plus: A randomized phase III trial of Pemetrexed and Bevacizumab vs. Pemetrexed, Bevacizumab and Carboplatin as 1st line treatment for elderly patients with advanced non-squamous, non-small cell lung cancer (NSCLC) - a subgroup analysis of age and gender
Schuette, W.
Nieman, B.
Schneider, C. P.
Engel-Riedel, W.
Schumann, C.
Kohlhaeufl, M.
Serke, M.
Hoeffken, G.
Kortsik, C.
Reck, M.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S623 - S623
[32] Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab for Japanese nonsquamous non-small cell lung cancer
Yokoi, Takashi
Torii, Yoshitaro
Katashiba, Yuichi
Sugimoto, Hiroyuki
Hayashi, Mina
Shimizu, Toshiki
Nomura, Shosaku
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[33] A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer
Yabuki, Yohei
Otsuka, Kenji
Ogino, Hirokazu
Takeuchi, Eiji
Haku, Takashi
Kanematsu, Takanori
Nishimura, Naoki
Toyoda, Yuko
Hanibuchi, Masaki
Mitsuhashi, Atsushi
Tsukazaki, Yuki
Ozaki, Ryohiko
Yoneda, Hiroto
Nokihara, Hiroshi
Nisihioka, Yasuhiko
RESPIROLOGY, 2023, 28 : 300 - 300
[34] Anlotinib plus carboplatin/pemetrexed in treatment-naive advanced non-squamous NSCLC: An open-label, randomized, phase II study
Guo, R.
Gao, W.
Li, J.
Liu, Y.
Liu, X.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S801 - S801
[35] Bevacizumab with Docetaxel or S-1 in Non-Squamous NSCLC (HANSHIN 0110)
Tachihara, Motoko
Nishino, Kazumi
Tamura, Daisuke
Kumagai, Toru
Imamura, Fumio
Okuda, Chiyuki
Hata, Akito
Katakami, Nobuyuki
Urata, Yoshiko
Hattori, Yoshihiro
Satouchi, Miyako
Yoneda, Tsutomu
Yokota, Soichiro
Nishimura, Takashi
Kaneda, Toshihiko
Nishimura, Yoshihiro
Morita, Satoshi
Negoro, Shunichi
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S547 - S547
[36] Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
Koji Nishimoto
Masato Karayama
Naoki Inui
Hideki Yasui
Hironao Hozumi
Yuzo Suzuki
Kazuki Furuhashi
Tomoyuki Fujisawa
Noriyuki Enomoto
Yutaro Nakamura
Nao Inami
Shun Matsuura
Yusuke Kaida
Takashi Matsui
Kazuhiro Asada
Hiroyuki Matsuda
Masato Fujii
Mikio Toyoshima
Shiro Imokawa
Takafumi Suda
Medical Oncology, 2018, 35
[37] Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
Nishimoto, Koji
Karayama, Masato
Inui, Naoki
Yasui, Hideki
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Fujisawa, Tomoyuki
Enomoto, Noriyuki
Nakamura, Yutaro
Inami, Nao
Matsuura, Shun
Kaida, Yusuke
Matsui, Takashi
Asada, Kazuhiro
Matsuda, Hiroyuki
Fujii, Masato
Toyoshima, Mikio
Imokawa, Shiro
Suda, Takafumi
MEDICAL ONCOLOGY, 2018, 35 (07)
[38] Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG)
Kotsakis, A.
Kentepozidis, N.
Emmanouilidis, Ch.
Polyzos, A.
Agelidou, A.
Vaslamatzis, M.
Chandrinos, V.
Agelaki, S.
Vamvakas, L.
Kalbakis, K.
Katsaounis, P.
Stoltidis, D.
Nintos, G.
Hatzidaki, D.
Vetsika, E. K.
Mavroudis, D.
Georgoulias, V.
LUNG CANCER, 2015, 88 (01) : 57 - 62
[39] Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life-Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer (ERACLE)
Galetta, Domenico
Pisconti, Salvatore
Cinieri, Saverio
Pappagallo, Giovanni Luigi
Gebbia, Vittorio
Borsellino, Nicola
Maiello, Evaristo
Rinaldi, Antonio
Montrone, Michele
Rizzo, Pietro
Marzano, Nicola
Sasso, Nicola
Febbraro, Antonio
Colucci, Giuseppe
CLINICAL LUNG CANCER, 2011, 12 (06) : 402 - 406
[40] Safety of Bevacizumab (B) in Elderly Stage IV Non-Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study
Juan, Oscar
Aparisi, Francisco
Llorente, Mar
Massuti, Bartomeu
Sanchez-Hernandez, Alfredo
Martin, Maria
Blasco Cordellat, Sara
Blasco, Ana
Girones, Regina
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S916 - S916

← 1 2 3 4 5 →